<DOC>
	<DOCNO>NCT00357903</DOCNO>
	<brief_summary>This study design provide adult pediatric arthritis patient ( placebo etanercept ( TNFR : Fc ) treat ) participate clinical trial etanercept ( TNFR : Fc ) opportunity receive continue treatment etanercept ( TNFR : Fc ) . The primary objective study examine safety parameter .</brief_summary>
	<brief_title>Open-Label Extension Treatment With Etanercept ( TNFR : Fc ) Participating Patients Etanercept ( TNFR : Fc ) Clinical Trials</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Previous enrollment Immunex protocols No clinically significant adverse event think due etanercept ( TNFR : Fc ) previous treatment . Negative serum pregnancy test 14 day first dose study drug female childbearing potential . No one NSAID dose great maximum recommend dose stable least two week prior administration etanercept ( TNFR : Fc ) . Previous receipt TNFR : Fc ( p55 ) , antibody TNF , antiCD4 antibody , diphtheria IL2 fusion protein . Receipt investigational drug biologics ( TNFR : Fc [ p75 ] ) within 1 month prior first dose etanercept ( TNFR : Fc ) study . Receipt DMARDs methotrexate ( except patient 16.0014 ) within two week prior first dose etanercept ( TNFR : Fc ) study . Receipt cyclophosphamide within six month prior first dose ( etanercept ( TNFR : Fc ) study . Receipt cyclosporin within two week prior first dose etanercept ( TNFR : Fc ) study .</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Rheumatoid Arthritis , Etanercept , Long-term Safety , Enbrel</keyword>
</DOC>